Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirogabalin for oxaliplatin-induced peripheral neuropathy
jRCT1041210094Phase 2Recruiting
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mirogabalin in Peripheral neuropathic pain, chemotherapy-induced peripheral neuropathy (CIPN) and peripheral neuropathy (CIPN). Primary endpoint: Tingling 30% improvement rate. Started Nov 2021; status: recruiting.
02
Drugs
mirogabalin
03
Conditions
Peripheral neuropathic painchemotherapy-induced peripheral neuropathy (CIPN)peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on jRCT1041210094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041210094.